SCHEMBL5000619

SCHEMBL5000619

COc1ccc(N2CCN(c3cncc(-c4ccccc4)n3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.60
ALDH1A1 P00352 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
RAB9A P51151 3/20 0.60
NPC1 O15118 2/20 0.60
KDM4E B2RXH2 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SIRT1 Q96EB6 1/20 0.52
KMT2A Q03164 1/20 0.48
RECQL P46063 1/20 0.46
HRH1 P35367 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
CHEK1 O14757 2/20 0.45
ABL1 P00519 1/20 0.45
NTRK1 P04629 1/20 0.45
YES1 P07947 1/20 0.45
PIM1 P11309 1/20 0.45
MAPK1 P28482 1/20 0.45
KDR P35968 1/20 0.45
HIPK1 Q86Z02 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996925 0.89 MAPT (0.53) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4992338 0.88 NPC1 (0.61) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4997409 0.88 L3MBTL1 (0.52) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL5000709 0.87 ALDH1A1 (0.50) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4991471 0.86 CYP1A2 (0.57) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4993281 0.86 MAPT (0.54) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4996226 0.85 CHEK1 (0.48) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4997547 0.84 MAPT (0.48) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4994760 0.84 CHEK1 (0.65) MAPTALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4995514 0.83 HPGD (0.46) MAPTALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C MAPT 5/4885ALDH1A1 1034/4885SMN1; SMN2 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.